Revere Health First In Utah To Offer Hybrid Closed Loop Technology To People With Type 1 Diabetes

PROVO, UT – June 15, 2017 – Revere Health is proud to be the first medical center in Utah to offer the MiniMed^® 670G system—the first FDA-approved hybrid closed loop system. This advanced system is the first insulin pump to automatically deliver a personalized amount of background (basal) insulin needed by the body 24 hours a day. For type 1 patients who don’t have the ability to produce insulin like those with a healthy pancreas, this system will learn their insulin needs via an intelligent algorithm and deliver a tailored amount of insulin every 5 minutes to maximize the time their glucose levels stay in a healthy range.

“We’re very excited to introduce this groundbreaking technology to Utah residents,” says Revere Health endocrinologist Souhbi Nizam, MD, FACE, CCD.  “Type 1 patients wearing the pump should encounter fewer short- and long-term diabetic complications, and experience better blood sugar control, less blood sugar fluctuation and less hypoglycemia.”

Physicians anticipate the device will also decrease the time-intensive burden of diabetes management and the associated mental stress. While most current pumps on the market are reactive, meaning they deliver insulin if levels drop too low, the MiniMed 670G system acts proactively to help prevent severe highs and lows.

“This system is truly life changing for patients with type 1 diabetes,” says Revere Health diabetes educator and insulin pump trainer Clarene Hansen, FNP. “Patients will feel ‘more normal’, be more productive and lead healthier, less stressful lives.”

The MiniMed 670G system features the new Guardian^® Sensor 3, Medtronic’s newest and most advanced glucose sensor with enhanced accuracy and performance, and a longer 7-day life. The system is approved for patients with type 1 diabetes ages 14 years of age or older.

Type 1 diabetes is an autoimmune disease that results when the pancreas stops making insulin. Of those who live with diabetes, about 5 percent have type 1 diabetes. The prevalence of diabetes is growing and today approximately 1.25 million American children and adults have type 1 diabetes.

About MiniMed® 670G System

The MiniMed 670G system is the first and only device approved by the FDA to automatically deliver a personalized amount of basal insulin 24 hours a day. The system features Medtronic’s most advanced algorithm to date, SmartGuard^® HCL. This intelligent algorithm is designed to learn an individual’s needs and deliver a variable rate of insulin every five minutes, maximizing the time glucose levels are within the target range. This first of its kind hybrid closed loop system is integrated with the company’s new Guardian Sensor 3 – Medtronic’s most accurate sensor to date with longer seven day wear. The system is FDA approved for the treatment of people with type 1 diabetes ages 14 years and older.

---

Important Safety Information for Medtronic MiniMed 670G^® System

 The Medtronic MiniMed 670G system is intended for continuous delivery of basal insulin (at user selectable rates) and administration of insulin boluses (in user selectable amounts) for the management of type 1 diabetes mellitus in persons, fourteen years of age and older, requiring insulin as well as for the continuous monitoring and trending of glucose levels in the fluid under the skin. The MiniMed 670G system includes SmartGuard technology, which can be programmed to automatically adjust delivery of basal insulin based on continuous glucose monitor sensor glucose values, and can suspend delivery of insulin when the sensor glucose value falls below or is predicted to fall below predefined threshold values. The system requires a prescription. The Guardian Sensor (3) glucose values are not intended to be used directly for making therapy adjustments, but rather to provide an indication of when a fingerstick may be required. A confirmatory finger stick test via the CONTOUR®NEXT LINK 2.4 blood glucose meter is required prior to making adjustments to diabetes therapy. All therapy adjustments should be based on measurements obtained using the CONTOUR®NEXT LINK 2.4 blood glucose meter and not on values provided by the Guardian Sensor (3).  Always check the pump display to ensure the glucose result shown agrees with the glucose results shown on the CONTOUR®NEXT LINK 2.4 blood glucose meter. Do not calibrate your CGM device or calculate a bolus using a blood glucose meter result taken from an alternative site (palm) or from a control solution test. Do not calibrate your CGM device when sensor or blood glucose values are changing rapidly, e.g., following a meal or physical exercise.  If a control solution test is out of range, please note that the result may be transmitted to your pump when in the “Always” send mode. WARNING: Medtronic performed an evaluation of the MiniMed 670G system and determined that it may not be safe for use in children under the age of 7 because of the way that the system is designed and the daily insulin requirements. Therefore this device should not be used in anyone under the age of 7 years old. This device should also not be used in patients who require less than a total daily insulin dose of 8 units per day because the device requires a minimum of 8 units per day to operate safely. Only use rapid acting U100 insulin with this system. Pump therapy is not recommended for people whose vision or hearing does not allow recognition of pump signals and alarms. Pump therapy is not recommended for people who are unwilling or unable to maintain contact with their healthcare professional. The safety of the MiniMed 670G system has not been studied in pregnant women. For complete details, including product and important safety information concerning the system and its components, please consult http://www.medtronicdiabetes.com/important-safety-information#minimed-670g and the appropriate user guide at http://www.medtronicdiabetes.com/download-library.

---

  http://www.diabetes.org/diabetes-basics/statistics/?referrer=https://www.google.com/#sthash.RJREjQlK.dpuf